Information Provided By:
Fly News Breaks for April 24, 2019
EW
Apr 24, 2019 | 08:47 EDT
Jefferies analyst Raj Denhoy raised his price target for Edwards Lifesciences to $210 from $195 saying the company remains well positioned for 10%-plus growth following its Q1 results. He sees 2019 as "another big year" in transcather therapies and keeps a Buy rating on the shares.